US2023390281A1PendingUtilityA1

Opioid for use to reduce and/or drug addiction

Assignee: DMK PHARACEUTICAL CORPPriority: Apr 30, 2017Filed: Aug 15, 2023Published: Dec 7, 2023
Est. expiryApr 30, 2037(~10.7 yrs left)· nominal 20-yr term from priority
Inventors:Ebrahim Versi
A61K 31/496A61P 25/30A61K 31/135A61P 25/36A61K 31/137
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method of treating drug addiction and reducing dependence or tolerance on a dependence-inducing opiate drug, wherein the method comprises administering to a subject a compound having the structure of formula (I): having the IUPAC name of (−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol, or pharmaceutically acceptable esters or salts thereof, wherein the compound has activity on the mu, delta and kappa opioid receptors thereby providing added analgesia with an improved therapeutic index and reduced risk of respiratory depression.

Claims

exact text as granted — not AI-modified
That which is claimed is: 
     
         1 . A pharmaceutical composition to reduce tolerance of an opioid or opioid like comprising, the pharmaceutical composition comprising:
 (a) an opioid or an opioid like compound for treatment of a condition selected from the group consisting of drug addiction or drug overdose; and   (b) an effective amount of a compound comprising the formula:   
       
         
           
           
               
               
           
         
         (−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol or a pharmaceutically acceptable salt or esters thereof. 
       
     
     
         2 . The composition of  claim 1 , wherein opioid or an opioid like compound is selected from the group consisting of methadone, codeine, thebaine, dihydrocodeine, hydrocodone, hydromorphone, nicomorphine, oxycodone, oxymorphone, alphamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanyl, ohmefentanyl, nocaine, pethidine (meperidine), ketobemidone, MPPP, allylprodine, prodine, PEPAP, propoxyphene, dextropropoxyphene, dextromoramide, bezitramide, piritramide, methadone, dipipanone, levo-alphacetylmethadol (LAAM), loperamide, diphenoxylate, pentazocine, phenazocine, buprenorphine, etorphine, butorphanol, nalbuphine, levorphanol, levomethorphan, dezocine, lefetamine, tilidine, tramadol, propoxyphene, or oxycodone.

Join the waitlist — get patent alerts

Track US2023390281A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.